Literature DB >> 8521414

Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines.

G I Shapiro1, J E Park, C D Edwards, L Mao, A Merlo, D Sidransky, M E Ewen, B J Rollins.   

Abstract

p16INK4A, a specific inhibitor of cyclin-dependent kinase (cdk)4 and cdk6, is a candidate tumor suppressor in malignancies with wild-type retinoblastoma (Rb). Loss of p16INK4A frees these cdks from inhibition, permitting constitutive phosphorylation of Rb and inactivation of its growth suppressive properties. Consistent with this model, Rb-positive non-small cell lung cancers (NSCLCs) have little or no detectable p16INK4A protein, whereas Rb-negative lung cancers have abundant p16INK4A. However, only some NSCLCs have homozygous deletions or nonsense mutations in a remaining p16INK4A allele, suggesting that other mechanisms must account for absent or low levels of p16INK4A protein. Here, we analyzed 9 Rb-positive NSCLC cell lines for the controls governing p16INK4A activity. Four lines had homozygous deletions of p16INK4A (SK-LU-1, SK-MES-1, A-427, and SW900), and three had a point mutation in a single allele. First, in H520 cells, the previously reported deletion at codon 45 results in a frameshift that produces no detectable protein. Second, in Calu-3 cells, a His to Tyr substitution at codon 83 produced a variant with a shortened half-life that was unable to form complexes with cdk4 or cdk6. Third, in H661 cells, the previously reported point mutation in the second intron splice donor site resulted in a smaller p16INK4A protein. Although this variant formed complexes with cdk4 and cdk6, it had a profoundly reduced half-life, producing low steady-state levels of p16INK4A and abundant levels of free cdks. Finally, Calu-1 and Calu-6 cells transcribed no detectable mRNA encoding authentic p16INK4A. These cell lines displayed methylation of the CpG island surrounding the first exon of p16INK4A and expressed abundant levels of a nontranslated mRNA containing an alternative first exon (E1 beta), as did all other cell lines in which the p16INK4A locus was not deleted. These data indicate that Rb-positive NSCLC cells have evolved a variety of pathways to suppress p16INK4A expression. Reintroduction of p16INK4A into these cell lines by retroviral transfer resulted in a reduced growth rate, increased abundance of hypophosphorylated Rb, accumulation of cells in G1, and a less transformed morphology in Rb-positive, but not Rb-negative cells, suggesting that loss of p16INK4A is essential for maintenance of the transformed phenotype.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8521414

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

1.  Differential expression of critical cellular genes in human lung adenocarcinomas and squamous cell carcinomas in comparison to normal lung tissues.

Authors:  Amy L McDoniels-Silvers; Gary D Stoner; Ronald A Lubet; Ming You
Journal:  Neoplasia       Date:  2002 Mar-Apr       Impact factor: 5.715

Review 2.  Molecular genetic abnormalities in the pathogenesis of human lung cancer.

Authors:  E Forgacs; S Zöchbauer-Müller; E Oláh; J D Minna
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

3.  Expression, deletion [was deleton] and mutation of p16 gene in human gastric cancer.

Authors:  X S He; Q Su; Z C Chen; X T He; Z F Long; H Ling; L R Zhang
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

4.  Expression of p16 gene and Rb protein in gastric carcinoma and their clinicopathological significance.

Authors:  Xiu-Sheng He; Ying-Hui Rong; Qi Su; Qiao Luo; Dong-Mei He; Yan-Lan Li; Yan Chen
Journal:  World J Gastroenterol       Date:  2005-04-21       Impact factor: 5.742

Review 5.  Lung cancer. 1: prevention of lung cancer.

Authors:  G E Goodman
Journal:  Thorax       Date:  2002-11       Impact factor: 9.139

6.  Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors.

Authors:  Young Shin Cho; Hayley Angove; Christopher Brain; Christine Hiu-Tung Chen; Hong Cheng; Robert Cheng; Rajiv Chopra; Kristy Chung; Miles Congreve; Claudio Dagostin; Deborah J Davis; Ruth Feltell; John Giraldes; Steven D Hiscock; Sunkyu Kim; Steven Kovats; Bharat Lagu; Kim Lewry; Alice Loo; Yipin Lu; Michael Luzzio; Wiesia Maniara; Rachel McMenamin; Paul N Mortenson; Rajdeep Benning; Marc O'Reilly; David C Rees; Junqing Shen; Troy Smith; Yaping Wang; Glyn Williams; Alison J-A Woolford; Wojciech Wrona; Mei Xu; Fan Yang; Steven Howard
Journal:  ACS Med Chem Lett       Date:  2012-05-17       Impact factor: 4.345

7.  Silibinin inhibits human nonsmall cell lung cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulators.

Authors:  Samiha Mateen; Alpna Tyagi; Chapla Agarwal; Rana P Singh; Rajesh Agarwal
Journal:  Mol Carcinog       Date:  2010-03       Impact factor: 4.784

Review 8.  Control of stress signaling in stem cells: crossroads of stem cells and cancer.

Authors:  Seung-Ju Cho; JaeHyung Koo; Kwang-Hoon Chun; Hyuk-Jin Cha
Journal:  Tumour Biol       Date:  2016-07-27

9.  Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression.

Authors:  V G Gorgoulis; P Zacharatos; A Kotsinas; T Liloglou; A Kyroudi; M Veslemes; A Rassidakis; T D Halazonetis; J K Field; C Kittas
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

10.  Co-expression of p16(INK4A) and laminin 5 gamma2 by microinvasive and superficial squamous cell carcinomas in vivo and by migrating wound and senescent keratinocytes in culture.

Authors:  Easwar Natarajan; Marcela Saeb; Christopher P Crum; Sook B Woo; Phillip H McKee; James G Rheinwald
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.